Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Corneal Neovascularization - Overview
Corneal Neovascularization - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Corneal Neovascularization - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Corneal Neovascularization - Companies Involved in Therapeutics Development
Chengdu Kanghong Pharmaceuticals Group Co Ltd
EyeGate Pharmaceuticals Inc
FortuneRock (Chi) Ltd
Gene Sigl Intertiol SA
Singh Biotechnology LLC
Wntgen LLC
Corneal Neovascularization - Drug Profiles
aganirsen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides to target VEGFR1 for Ophthalmology and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Corneal Neovascularization - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Raver-2 Protein for Ophthalmology Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit VEGF-A for Corneal Neovascularization - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JDE-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KH-906 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Proteins for Oncology and Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBT-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SFR-9X0122 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Wnt-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Corneal Neovascularization - Dormant Projects
Corneal Neovascularization - Product Development Milestones
Featured News & Press Releases
May 12, 2014: Gene Sigl announces positive data from Phase III trial of aganirsen eye drops for corneal neovascularisation due to inflammation, a rare eye disease with European Orphan Drug desigtion.
Jul 01, 2010: Results of a Meta-Alysis Show Neovascularization Increases Risk For Corneal Transplant Rejection And Failure
Sep 01, 2009: Gene Sigl GS-101 Data Shows Safe And Effective Inhibition Of Ophthalmic Blood Vessel Growth
Aug 11, 2009: Gene Sigl Announces Publication of Phase I Data Highlighting Safety of GS-101 For Diseases Of The Eye
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Corneal Neovascularization, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development for Corneal Neovascularization, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Corneal Neovascularization - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2020
Corneal Neovascularization - Pipeline by EyeGate Pharmaceuticals Inc, H2 2020
Corneal Neovascularization - Pipeline by FortuneRock (China) Ltd, H2 2020
Corneal Neovascularization - Pipeline by Gene Signal International SA, H2 2020
Corneal Neovascularization - Pipeline by Singh Biotechnology LLC, H2 2020
Corneal Neovascularization - Pipeline by Wntgen LLC, H2 2020
Corneal Neovascularization - Dormant Projects, H2 2020